Lars Hansen

Low Physical Activity Accentuates the Effect of the <i>FTO</i> rs9939609 Polymorphism on Body Fat Accumulation

Camilla Andreasen, Kirstine L. Stender-Petersen, Mette Sloth Mogensen et al. · Diabetes · 2007 · 477 citations · Full text

Medicine, Endocrinology, Genetics +16

Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial

Paresh Dandona, Chantal Mathieu, Moshe Phillip et al. · The Lancet Diabetes & Endocrinology · 2017 · 292 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +10

Dual Add-on Therapy in Type 2 Diabetes Poorly Controlled With Metformin Monotherapy: A Randomized Double-Blind Trial of Saxagliptin Plus Dapagliflozin Addition Versus Single Addition of Saxagliptin or Dapagliflozin to Metformin

Julio Rosenstock, Lars Hansen, Pamela Zee et al. · Diabetes Care · 2014 · 287 citations

Medicine, Pharmacology, Pharmacotherapy +17

Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial

Paresh Dandona, Pieter Gillard, Peter Senior et al. · Diabetes Care · 2018 · 252 citations

Medicine, Pharmacology, Pharmacotherapy +15

Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study

Paresh Dandona, Chantal Mathieu, Moshe Phillip et al. · Diabetes Care · 2018 · 238 citations

Medicine, Pharmacology, Pharmacotherapy +17